Kollár J, Rozdobud'ková V, Koprovicová J, Rajnová E, Seiler J
Ustav experimentálnej medicíny Lekárskej fakulty P. J. Safárika Kosice.
Vnitr Lek. 1991 May;37(5):470-8.
Etolip is the first Czechoslovak hypolipidaemic preparation produced in the Pharmaceutical Research Institute in Modra. As to the chemical structure it is ethophylline clofibrate. It was administered to 39 manual workers with hyperlipoproteinaemia type IIa, IIb, III, IV and V-500 mg/day, i.e. 2-0-2 capsules. The mean age of the patients varied round 43 +/- 6.1 years. They were subdivided into study possible, comparing Lipanthyl and Etolip. Despite the fact that the subjects did not adhere to a strict diet and occasionally consumed 50-100 g alcohol, Etolip (E) reduced the triacylglycerol concentration (TG) in serum for a period of one month after administration on average by 28% (p less than 0.01) in workers with hyperlipoproteinaemia (HL) type IIb, III, IV and V. In group A it is reduced from 2.8 +/- 1.0 mmol/l to 1.7 +/- 0.5 mmol/l and in group B from 2.4 +/- 1.0 mmol/l to 2.0 +/- 1.0 mmol/l. The total cholesterol concentration (CH) in serum declines after E on average in both groups by 11.4% (p less than 0.01) in the mentioned types of HL, whereby in subjects with HL type IIa and III it is practically unchanged. The apolipoprotein B concentration declines in serum of groups A and B from 185.6 +/- 37.8 to 137.5 +/- 44.2 mg/dl and from 144.9 +/- 27.9 to 113.3 +/- 23.6 mg/dl. After one month treatment with this drug the blood sugar level, and serum creatinine concentration does not rise, the haemogram and the uric acid concentration do not change. E raises the AST and ALT concentration to double the initial value which is still at the borderline of normal values.
益多脂是摩德拉制药研究所生产的第一种捷克斯洛伐克降血脂制剂。就化学结构而言，它是氯贝酸乙茶碱。对39名患有IIa型、IIb型、III型、IV型和V型高脂蛋白血症的体力劳动者给药，剂量为每日500毫克，即2-0-2粒胶囊。患者的平均年龄约为43±6.1岁。他们被分为研究组，比较力平脂和益多脂。尽管受试者没有严格遵守饮食规定，偶尔还摄入50-100克酒精，但益多脂（E）在给药后一个月内，使IIb型、III型、IV型和V型高脂蛋白血症（HL）患者血清中的三酰甘油浓度（TG）平均降低了28%（p<0.01）。在A组中，它从2.8±1.0毫摩尔/升降至1.7±0.5毫摩尔/升，在B组中从2.4±1.0毫摩尔/升降至2.0±1.0毫摩尔/升。在上述类型的HL患者中，两组血清总胆固醇浓度（CH）在服用E后平均下降了11.4%（p<0.01），而在IIa型和III型HL患者中实际上没有变化。A组和B组血清载脂蛋白B浓度从185.6±37.8降至137.5±44.2毫克/分升，从144.9±27.9降至113.3±23.6毫克/分升。用这种药物治疗一个月后，血糖水平和血清肌酐浓度没有升高，血常规和尿酸浓度没有变化。E使AST和ALT浓度升高至初始值的两倍，但仍处于正常值的临界范围内。
